Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Metastasis02:30

Metastasis

7.0K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
7.0K
Disorders of Leukocytes01:27

Disorders of Leukocytes

2.5K
Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune...
2.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

5.0K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Age and sex-based differences in therapy preferences among patients with cancer: evidence from a novel therapy preference scale.

Ecancermedicalscience·2026
Same author

Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

American journal of hematology·2026
Same author

NCCN Guidelines® Insights: Acute Myeloid Leukemia, Version 3.2026.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Adoption of an Early Enteral Nutrition Feeding Protocol in Patients Receiving an Allogeneic Stem Cell Transplant.

Nutrients·2026
Same author

Safety and Efficacy of Direct Oral Anticoagulants Compared to Warfarin in Patients with Venous Thromboembolism and Morbid Obesity.

International journal of hematology-oncology and stem cell research·2026
Same author

A phase I, single-arm, open-label, dose-escalation, multicenter study of SAR445419, an off-the-shelf, ex vivo expanded allogeneic natural killer cell product, in participants with relapsed or refractory acute myeloid leukemia.

Cancer immunology, immunotherapy : CII·2026

Related Experiment Video

Updated: Apr 19, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

957

Leukemic transformation in essential thrombocythemia.

Vijaya Raj Bhatt

    Future Oncology (London, England)
    |December 23, 2014
    PubMed
    Summary
    This summary is machine-generated.

    Essential thrombocythemia can transform into acute myeloid leukemia (AML) in 1-4% of patients, with risk factors including age and mutations. Certain treatments increase AML risk, necessitating tailored therapeutic approaches.

    Keywords:
    CALR mutationJAK2 V617F mutationacute myeloid leukemiaallogeneic stem cell transplantationcytoreductive drugsessential thrombocythemiainduction chemotherapy

    More Related Videos

    Assessment of the Metabolic Profile of Primary Leukemia Cells
    06:21

    Assessment of the Metabolic Profile of Primary Leukemia Cells

    Published on: November 21, 2018

    11.1K
    Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
    09:09

    Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

    Published on: November 10, 2017

    9.0K

    Related Experiment Videos

    Last Updated: Apr 19, 2026

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
    07:38

    Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

    Published on: June 6, 2025

    957
    Assessment of the Metabolic Profile of Primary Leukemia Cells
    06:21

    Assessment of the Metabolic Profile of Primary Leukemia Cells

    Published on: November 21, 2018

    11.1K
    Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation
    09:09

    Preparation of Primary Acute Lymphoblastic Leukemia Cells in Different Cell Cycle Phases by Centrifugal Elutriation

    Published on: November 10, 2017

    9.0K

    Area of Science:

    • Hematology
    • Oncology

    Background:

    • Essential thrombocythemia (ET) is a myeloproliferative neoplasm.
    • A subset of ET patients may develop acute myeloid leukemia (AML).

    Purpose of the Study:

    • To summarize the risk factors, treatment implications, and prognostic considerations for AML development in ET patients.
    • To outline management strategies for AML in the context of ET.

    Main Methods:

    • Review of existing literature on ET transformation to AML.
    • Analysis of risk factors, including patient demographics, clinical features, genetic mutations, and prior therapies.
    • Evaluation of treatment outcomes and prognostic indicators for AML in ET.

    Main Results:

    • AML develops in 1-4% of ET patients over 7-10 years.
    • Risk factors include advanced age, anemia, high platelet counts, multiple somatic mutations, and time since diagnosis.
    • Alkylating agents and (32)radiophosphorus increase AML risk; hydroxyurea and anagrelide do not.
    • AML in ET often presents with unfavorable cytogenetics and poor prognosis.

    Conclusions:

    • AML transformation in ET is a significant concern with specific risk factors and treatment associations.
    • Treatment strategies for AML in ET vary based on patient fitness, including chemotherapy with stem cell transplant or hypomethylating agents.